MENEST

Post-LOE

esterified estrogens

Monarch Therapeutics

ANDAORALTABLET

Approved

Sep 1977

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

MENEST (esterified estrogens) by Monarch Therapeutics is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Approved for the: 1, breast cancer. First approved in 1977.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…

Worked on MENEST at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

MENEST

Mechanism of Action

Indications (2)